Pregabalin: a novel gamma-aminobutyric acid analogue in the treatment of neuropathic pain, partial-onset seizures, and anxiety disorders
The responder rate to the CGI-I was defined as a CGI-I score of 2 or less (much or very much improved). Furthermore, the number of patients discontinuing treatment in each group, reasons for discontinuation (lack of efficacy or adverse events), costs of the drug, total costs, and quality-adjusted life years (QALYs) were evaluated. Sleep disturbances […]
